Vir Biotechnology Appoints Jason O’Byrne as Chief Financial Officer
Vir Biotechnology (Nasdaq: VIR) has appointed Jason O'Byrne as Executive Vice President and Chief Financial Officer, effective October 2, 2024. O'Byrne brings over 20 years of experience in finance and operations to Vir. He joins from Caribou Biosciences, where he served as CFO, and previously held senior roles at Audentes Therapeutics and Genentech. O'Byrne's expertise spans capital allocation, corporate strategy, and operational execution.
CEO Marianne De Backer praised O'Byrne's exceptional leadership and proven track record in financial strategy across public companies. O'Byrne expressed excitement about joining Vir as it expands into oncology and continues work in infectious diseases. His appointment aims to support Vir's mission of advancing innovative antibody therapeutics.
Vir Biotechnology (Nasdaq: VIR) ha nominato Jason O'Byrne come Vice Presidente Esecutivo e Direttore Finanziario, con effetto dal 2 ottobre 2024. O'Byrne porta con sé oltre 20 anni di esperienza in finanza e operazioni a Vir. Proviene da Caribou Biosciences, dove ha ricoperto il ruolo di CFO, e in precedenza ha occupato posizioni di rilievo in Audentes Therapeutics e Genentech. L'expertise di O'Byrne comprende allocazione di capitale, strategia aziendale e esecuzione operativa.
Il CEO Marianne De Backer ha elogiato l'eccezionale leadership di O'Byrne e il suo comprovato record nella strategia finanziaria per aziende quotate. O'Byrne ha espresso entusiasmo nell'unirsi a Vir mentre si espande nell'oncologia e continua il lavoro nelle malattie infettive. La sua nomina mira a sostenere la mission di Vir di promuovere terapie innovative con anticorpi.
Vir Biotechnology (Nasdaq: VIR) ha designado a Jason O'Byrne como Vicepresidente Ejecutivo y Director Financiero, a partir del 2 de octubre de 2024. O'Byrne aporta más de 20 años de experiencia en finanzas y operaciones a Vir. Se une a la compañía desde Caribou Biosciences, donde ocupó el cargo de CFO, y anteriormente tuvo roles destacados en Audentes Therapeutics y Genentech. La experiencia de O'Byrne abarca asignación de capital, estrategia corporativa y ejecución operativa.
La CEO Marianne De Backer elogió el liderazgo excepcional de O'Byrne y su trayectoria comprobada en estrategia financiera en empresas públicas. O'Byrne expresó su entusiasmo por unirse a Vir mientras se expande en oncología y continúa su trabajo en enfermedades infecciosas. Su nombramiento tiene como objetivo apoyar la misión de Vir de avanzar en terapias innovadoras con anticuerpos.
Vir Biotechnology (Nasdaq: VIR)는 제이슨 오바인(Jason O'Byrne)을 부사장 겸 최고재무책임자(CFO)로 임명했다고 발표했으며, 효력은 2024년 10월 2일부터 시작된다. 오바인은 Vir에서 20년 이상의 금융 및 운영 경험을 제공한다. 그는 CFO로 재직했던 Caribou Biosciences에서 합류했으며, 이전에는 Audentes Therapeutics와 Genentech에서 고위직을 역임했다. 오바인의 전문 분야는 자본 배분, 기업 전략 및 운영 실행이다.
CEO인 마리안 드 바커(Marianne De Backer)는 공기업의 재무 전략에서 오바인의 뛰어난 리더십과 입증된 성과를 칭찬했다. 오바인은 Vir에 합류하여 온콜로지(oncology)로의 확장과 감염병 연구를 계속하는 데 대한 기대감을 표명했다. 그의 임명은 Vir의 혁신적인 항체 치료제 개발 사명을 지원하는 것을 목표로 한다.
Vir Biotechnology (Nasdaq: VIR) a nommé Jason O'Byrne au poste de Vice-Président Exécutif et Directeur Financier, avec effet au 2 octobre 2024. O'Byrne apporte plus de 20 ans d'expérience dans les domaines de la finance et des opérations à Vir. Il rejoint l'entreprise en provenance de Caribou Biosciences, où il a occupé le poste de directeur financier, et a précédemment occupé des postes de direction chez Audentes Therapeutics et Genentech. L'expertise d'O'Byrne couvre l'allocation de capital, la stratégie d'entreprise et l'exécution opérationnelle.
La PDG Marianne De Backer a salué le leadership exceptionnel de O'Byrne et son bilan éprouvé en matière de stratégie financière au sein d'entreprises cotées. O'Byrne a exprimé son enthousiasme à rejoindre Vir alors que l'entreprise s'étend dans le domaine de l'oncologie et poursuit son travail sur les maladies infectieuses. Sa nomination vise à soutenir la mission de Vir d'avancer dans le développement de thérapies innovantes par anticorps.
Vir Biotechnology (Nasdaq: VIR) hat Jason O'Byrne als Executive Vice President und Chief Financial Officer zum 2. Oktober 2024 ernannt. O'Byrne bringt mehr als 20 Jahre Erfahrung in den Bereichen Finanzen und Betrieb zu Vir. Er kommt von Caribou Biosciences, wo er als CFO tätig war, und hatte zuvor leitende Positionen bei Audentes Therapeutics und Genentech inne. O'Byrnes Fachwissen umfasst Kapitalallokation, Unternehmensstrategie und operative Umsetzung.
CEO Marianne De Backer lobte O'Byrnes außergewöhnliche Führungskompetenz und seine nachweisliche Erfolgsbilanz in der Finanzstrategie für börsennotierte Unternehmen. O'Byrne äußerte seine Vorfreude, zu Vir zu stoßen, da sich das Unternehmen in die Onkologie ausweitet und weiterhin an Infektionskrankheiten arbeitet. Seine Ernennung soll die Mission von Vir unterstützen, innovative Antikörpertherapeutika voranzutreiben.
- Appointment of a seasoned CFO with over 20 years of experience in biotech finance and operations
- Addition of expertise in capital allocation, corporate strategy, and operational execution
- Potential for improved financial leadership as the company expands into oncology
- None.
– Seasoned biotech executive brings decades of effective financial leadership to Vir –
Mr. O’Byrne is an accomplished executive with more than 20 years of experience in finance and operations. He is a recognized champion of financial discipline and brings demonstrated financial leadership in capital allocation and formation, corporate strategy, and operational execution.
Mr. O’Byrne joins Vir from Caribou Biosciences, Inc., where he served as CFO leading the finance, investor relations, corporate communications, IT, procurement and operations functions as the company advanced its pipeline of clinical-stage cell therapies in oncology and autoimmune disease. Prior to joining Caribou, Mr. O’Byrne served as Senior Vice President of Finance at Audentes Therapeutics, where he led financial operations of the gene therapy company. While at Audentes, Mr. O’Byrne oversaw the financial due diligence and integration related to the company’s acquisition by Astellas Pharma in 2020.
Earlier in his career, Mr. O’Byrne held roles of increasing responsibility and geographical reach at Genentech, a member of the Roche group. Over a 13-year period with Genentech, he built broad operational finance expertise across manufacturing, research, clinical development, business development and commercialization. During his tenure, he served as Regional Head of Commercial Finance for the
“I am delighted to welcome Jason to the Vir Executive Management Team and excited about the impact he will bring to Vir. Jason’s exceptional leadership coupled with his proven track record in financial strategy across public companies, make him the perfect fit as we embark on the next chapter for our organization,” said Marianne De Backer, Chief Executive Officer, Vir Biotechnology. “As a seasoned and well-respected cross-functional leader with a focus on excellence in execution, I look forward to partnering with Jason as we advance in our mission of powering the immune system to transform lives.”
“I am honored to join Vir at this important time as it expands into oncology and continues the innovative work to address unmet patient need in infectious disease,” said Mr. O’Byrne. “I admire Vir’s proven ability to accelerate differentiated antibody therapeutics. I am excited to join the talented team and contribute to rapidly advancing important new therapeutic options for patients.”
About Vir Biotechnology, Inc.
Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Vir’s clinical-stage portfolio includes infectious disease programs for chronic hepatitis delta and chronic hepatitis B infections, in addition to multiple oncology programs. Vir also has a preclinical portfolio of programs across a range of other infectious diseases and oncologic malignancies. Vir routinely posts information that may be important to investors on its website.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “plan,” “potential,” “aim,” “expect,” “anticipate,” “promising” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Vir’s expectations and assumptions as of the date of this press release. Forward-looking statements contained in this press release include, but are not limited to, statements regarding Vir’s strategy and plans, and its expectations related thereto, and potential of, and expectations for, Vir’s pipeline. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data or results observed during clinical trials or in data readouts; the occurrence of adverse safety events; risks of unexpected costs, delays or other unexpected hurdles; difficulties in collaborating with other companies; successful development and/or commercialization of alternative product candidates by Vir’s competitors; changes in expected or existing competition; delays in or disruptions to Vir’s business or clinical trials due to geopolitical changes or other external factors; and unexpected litigation or other disputes. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements, or the scientific data presented. Other factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Vir’s filings with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20240910506268/en/
Media
Arran Attridge
Senior Vice President, Corporate Communications
aattridge@vir.bio
Investors
Richard Lepke
Senior Director, Investor Relations
rlepke@vir.bio
Source: Vir Biotechnology Inc.
FAQ
Who is the new CFO of Vir Biotechnology (VIR)?
What is Jason O'Byrne's background before joining Vir Biotechnology (VIR)?
What areas is Vir Biotechnology (VIR) focusing on according to the new CFO appointment?
When will Jason O'Byrne start his role as CFO at Vir Biotechnology (VIR)?
